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Abstract
Aims To investigate the relationship between HbA1c and glucose in people with co-existing liver disease and diabetes
awaiting transplant, and in those with diabetes but no liver disease.
Methods HbA1c and random plasma glucose data were collected for 125 people with diabetes without liver disease and
for 29 people awaiting liver transplant with diabetes and cirrhosis. Cirrhosis was caused by non-alcoholic fatty liver
disease, hepatitis C, alcoholic liver disease, hereditary haemochromatosis, polycystic liver/kidneys, cryptogenic/non-
cirrhotic portal hypertension and a-1-antitrypsin-related disease.
Results Themedian (interquartile range)ageof thediabeteswithcirrhosis groupwas55 (49–63)years compared to60 (50–
71) years (P=0.13) in the group without cirrhosis. In the diabetes with cirrhosis group there were 21 men (72%) compared
with 86men (69%) in the groupwith diabetes andno cirrhosis (P=0.82).Of the groupwith diabetes and cirrhosis, 27 people
(93%) were of white European ethnicity, two (7%) were South Asian and none was of Afro-Caribbean/other ethnicity
compared with 94 (75%), 16 (13%), 10 (8%)/5 (4%), respectively, in the group with diabetes and no cirrhosis (P=0.20).
Median (interquartile range)HbA1cwas 41 (32–56)mmol/mol [5.9 (5.1–7.3)%] vs 61 (52–70)mmol/mol [7.7 (6.9–8.6)%]
(P<0.001), respectively, in the diabetes with cirrhosis group vs the diabetes without cirrhosis group. The glucose
concentrationswere8.4(7.0–11.2)mmol/lvs 7.3(5.2–11.5)mmol/l (P=0.17).HbA1cwasdepressedby20mmol/mol(1.8%;
P<0.001) in 28 participants with cirrhosis but elevated by 28 mmol/mol (2.6%) in the participant with a-1-antitrypsin
disorder.Thosewith cirrhosis anddepressedHbA1c had fewer larger erythrocytes, andhigher red cell distributionwidthand
reticulocyte count. Thiswas reflected in the positive association of glucosewithmean cell volume (r=0.39) andhaemoglobin
level (r=0.49)andthenegativeassociation forHbA1c (r=–0.28and r=–0.26, respectively) in thediabetesgroupwithcirrhosis.
Conclusion HbA1c is not an appropriate test for blood glucose in people with cirrhosis and diabetes awaiting transplant
as it reflects altered erythrocyte presentation.
Diabet. Med. 00: 1–9 (2018)
Introduction
Diabetes is a leading cause of liver disease, with cirrhosis
responsible for a considerable number of deaths in people with
diabetes in theUSA [1].Theassociation ismediatedbymultiple
mechanisms including dyslipidaemia and altered hepatic fatty
acid processing [2]. Peripheral insulin resistance may con-
tribute to the development of diabetes in people with hepatitis
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C [3] and cirrhosis [4]. Post-transplant diabetes is well
recognized, with HbA1c testing not being appropriate imme-
diately afterwards as a result of post-transplant anaemia [5]
and also rendered inaccurate by some drugs such as ribavirin
which is used for hepatitis C treatment [6].
In 2011, the WHO introduced HbA1c assessment for the
diagnosis ofdiabetesmellitus [7].HbA1c is nowwidelyused for
this purpose in primary care, resulting in a doubling of the
number of HbA1c assessments requested, and a corresponding
decrease in glucose measurement [8]. Since 2014, the use of
HbA1c testing has been included in the American Diabetes
Association guidelines for the diagnosis of diabetes in hospital
[9].This recommendationhasbeen confirmedbyassessmentof
undiagnosed diabetes inwhite Europeanpeople admitted to an
Irish hospital [10]. However, whilst the WHO bulletin lists
medicalconditionsanddrugsthatmayaffectHbA1c, itprovides
no references to quantitative evidence [7].
Our hospital laboratory has reviewed HbA1c test results,
referring values below the reference range or very high values
in people without a previous diagnosis of diabetes for urgent
medical attention [8,11]. Evidence is accumulating that
various co-existing conditions affect HbA1c and result in
misdiagnosis or mismanagement of diabetes [12]. Recently,
HbA1c was measured in 200 people with decompensated
cirrhosis referred for liver transplantation. Measured HbA1c
values were significantly lower when compared with HbA1c
calculated from three previous glucose values [13].
Given these concerns, we investigated random plasma
glucose and HbA1c in people recruited for research into the
relationships between glycaemic markers when attending
diabetes clinics at the hospital, and in people with co-existing
cirrhosis and diabetes awaiting liver transplant who had
available data on glycaemic markers andModel for End Stage
Liver Disease (MELD) scores [14].
Participants and methods
Ethics
The West Midlands Local Research Ethics Committee
confirmed ethical approval for the Glucose Fructosamine
and HbA1c research study investigating the relationships
between glycaemic markers in people attending the diabetes
clinic at University Hospitals Birmingham NHS Foundation
Trust. This study met the requirements of the current revision
of the Declaration of Helsinki.
For people with diabetes attending liver clinics between
June and September 2012, data were obtained from the
electronic patient record for a registered, internal clinical
audit (CAB-05641-13) at University Hospitals Birmingham
NHS Foundation Trust.
Study cohort
The people with diabetes without liver cirrhosis included
adults with no variant haemoglobin (n=125) who were
recruited from the diabetes clinic at Queen Elizabeth Hospital
Birmingham, University Hospitals Birmingham NHS Foun-
dation Trust, UK, between June 2007 and June 2009.
The people with co-existing liver cirrhosis and diabetes
comprised people from different parts of the UKwith cirrhosis
of the liver and diabetes, attending day clinics in the Liver
Department at Queen Elizabeth Hospital Birmingham, UK,
who were being considered for liver transplantation. Those
attending between October 2008 and June 2012 were
included in the clinical audit; in total, 240 people were
reviewed. HbA1c and random plasma glucose measurements,
performed at Queen Elizabeth Hospital Birmingham labora-
tories, were available for 29 out of the 50 transplant
candidates with both cirrhosis and diabetes. No othermeasure
of glycaemic control was available to the study. Indications for
transplant included one or more of the following complica-
tions of cirrhosis: spontaneous bacterial peritonitis; ascites;
variceal bleed; and hepatic encephalopathy. Of the 29
participants in this cohort, 15 (52%) had non-alcoholic fatty
liver disease, six (21%) had hepatitis C, three (10%) had
alcoholic liver disease, two (7%) had hereditary haemochro-
matosis, one (3%) had polycystic liver and kidneys, one (3%)
had a-1-antitrypsin-related liver disease and one (3%) had
cryptogenic/non cirrhotic portal hypertension. Data were
collected for this preliminary, clinical audit from the Birm-
ingham Systems Prescribing Information and Communica-
tions System and the CDS Telepath Systems Ltd databases.
Measurements
All measurements were performed at University Hospitals
Birmingham NHS Foundation Trust, with single measure-
ments of HbA1c, random plasma glucose, serum bilirubin
and creatinine, and full blood count. Blood was collected
What’s new?
• HbA1c may not be an accurate reflection of blood
glucose for the diagnosis/monitoring of diabetes in
people with other illnesses or on certain drugs; people
with diabetes and liver disease awaiting transplantation
are one such group.
• HbA1c was found to be depressed relative to random
plasma glucose by 20 mmol/mol in people with diabetes
and cirrhosis (n = 28) compared to people with diabetes
but no liver disease (n = 125); however, HbA1c was
elevated in one person with cirrhosis attributable to a-
1-antitrypsin disorder.
• Compromised HbA1c may be related to haematological
differences associated with liver disease involving ery-
throcyte half-life, with shorter/longer times giving
less/more opportunity for glycation of haemoglobin.
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into fluoride oxalate vacutainers for glucose measurement.
Biochemical variables were measured on Roche c8000
analysers (Roche Diagnostics Ltd, Burgess Hill, UK) and full
blood count on Beckman DxH800 analysers (Beckman
Coulter Ltd, High Wycombe, UK).
HbA1c was measured in EDTA blood using an Interna-
tional Federation of Clinical Chemistry and Laboratory
Medicine (IFCC) aligned TOSOH G8 ion exchange high
performance liquid chromatography analysers (Tosoh, Read-
ing, UK) before realignment of their calibrator downwards
by the manufacturer in September 2013 [15]. People with
abnormal haemoglobin were excluded because HbA1c is not
reported by the laboratory in its presence, as were people
with a total chromatogram area <500 as specified in the
manufacturer’s protocol for HbA1c measurement (~80g/l
haemoglobin).
The MELD score was calculated using the formula: [0.957
9 ln(serum creatinine) + 0.378 9 ln(serum bilirubin) + 1.120
9 ln(INR) + 0.643] 9 10, with creatinine set to 4.06 for
participants on haemodialysis [14]. The normal range for the
MELD score is 0 to 6, with a score of 40 defined as gravely
ill.
Statistical analysis
Data on participants without liver disease were entered into
an Excel spreadsheet with robust quality assurance. Bio-
chemical and haematological data were downloaded directly
from the laboratory Telepath database. Clinical audit data
for participants with diabetes and liver disease were
accessed in the electronic patient record and entered into a
pre-prepared Excel spreadsheet. Data were analysed with
Microsoft Excel, Analyse-it Version 2.22 (Analyse-it Soft-
ware Ltd, Leeds, UK), SPSS Statistics for Windows version
22.0 (IBM Corp., Armonk, NY, USA) and R version 3.4.0
[16].
The characteristics of the study cohort are presented in
Table 1 as median and interquartile range (IQR), count or
percentage, with Mann–Whitney or Fisher’s exact tests used
to compare the groups. Reference ranges were obtained from
the hospital laboratory. Simple linear regression was used to
assess the relationships between HbA1c and random plasma
glucose, with Fig. 1 showing regression lines for both groups
and 2SD lines for people with diabetes without cirrhosis.
Residual analysis was performed to assess the fit of the model
for the regression of HbA1c vs glucose. Some skewness in the
HbA1c data was demonstrated in a Normal Q-Q plot of
residuals, but there was no evidence of non-linearity. Log
transformation of HbA1c values reduced the skewness, but
did not affect the linearity, and yielded an R2 value of 0.44
rather than 0.42. As both models are valid and give similar
results, and given the ease of use of non-transformed data,
we have not used the log transformation. This has the added
advantage that the model is not dependent on the choice of
units for HbA1c.
Calculation of the difference in the HbA1c intercepts for
the people with co-existing liver cirrhosis and diabetes, and
people with diabetes without liver cirrhosis assumed the
slopes were equal. The equality of the slopes was assessed by
testing the glucose 9 group interaction term in a general
linear model for HbA1c, with glucose as a covariate and the
group as a factor.
The correlation grid shows results for 27 people with
diabetes and liver disease, and 123 with diabetes without
liver disease (Fig. 2). Correlations for people with co-existing
liver cirrhosis and diabetes are shown in the area of the grid
above the diagonal and, for people with diabetes without
liver cirrhosis, below the diagonal. The colour of the circles
indicates whether the correlations are positive or negative.
The intensity of the colour and the size of the circle are
proportional to the correlation coefficients [17].
Pearson coefficients were calculated for pairwise groupings
of each variable within the group, and displayed using the
CORRPLOT package in the R program v. 0.84 [17]. Correlation
coefficients were then compared using the R psych package v
1.7.8 [18]. Fisher transformations of correlation matrices
were created to compare correlation coefficients within and
between groups (psych::r.test function), and also when testing
the independence of the two groups (psych::corrtest function).
Significance tests were performed by establishing the Z-
score for the difference between the Fisher Z-transformed
correlations when divided by the standard error of the
difference between the two Z-scores. To confirm the
assumption that the groups are two distinct populations,
separable by the variables measured, a test of equivalence of
the Fisher Z-score equivalents of the two correlation matrices
was performed, which indicated two distinct groups (P<1.2e-
06, Z-score of differences = 4.98).
The profile of the participant with a-1-antitrypsin-related
liver disease was summarized graphically by expressing each
value as a multiple of the median value for that variable in
the group of people with diabetes without liver cirrhosis. The
median values for the people with co-existing cirrhosis and
diabetes disease (excluding the person with a-1-antitrypsin-
related liver disease) were plotted similarly, Fig. 3.
Results
Characteristics of participants
There were no significant differences in age, gender or
ethnicity, but serum creatinine was significantly lower in
people with diabetes and cirrhosis (P=0.001, Table 1). Two
distinct populations were identified when all the variables
were considered (P<0.001).
Glucose and HbA1c
Random plasma glucose concentrations did not differ, but
HbA1c was substantially lower in people with liver disease:
ª 2019 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK 3
Research article DIABETICMedicine
median (IQR) 41 (32–56) mmol/mol [5.9 (5.1–7.3)%] vs 61
(52–70) mmol/mol [7.7(6.9–8.6)%]; (P<0.001, Table 1 and
Fig. 1).
HbA1c and glucose were positively correlated: r
2=0.34 in
those with liver disease and r2=0.30 in those without
(P<0.001). Linear regression equations are cited in mmol/
mol (IFCC) and % (Diabetes Control and Complications
Trial/UK Prospective Diabetes Study) units:
liver disease: (mmol/mol) HbA1c ¼ 3:0 RPGþ 15:5; or
ð%Þ HbA1c ¼ 0:27 RPGþ 3:6
no liver disease: (mmol/mol) HbA1c ¼ 1:8 RPGþ 46:3;
or ð%Þ HbA1c ¼ 0:17 RPGþ 6:4;
where RPG is random plasma glucose. There was a signif-
icant difference of 20 mmol/mol (1.8%) HbA1c (P<0.001)
between the intercepts, assuming the slopes to be equal
(P=0.12). A similar result was obtained when the data were
restricted to white European people.
Haematology
There were major haematological differences between the
groups, with fewer red blood cells, and lower haemoglobin
and haematocrit levels in the group with diabetes and
cirrhosis; with the median values lower than the reference
ranges (Table 1). The red blood cell distribution width was
higher in those with liver disease and above the reference
range. The equivalent values for those with diabetes but no
cirrhosis were within the reference ranges. Higher values for
mean red blood cell volume and mean red blood cell
haemoglobin were found in the group with diabetes and
cirrhosis, indicating larger red blood cells, and also a higher
reticulocyte count, indicating a shorter half-life. People with
Table 1 Characteristics of people with liver cirrhosis and diabetes awaiting transplant vs people with diabetes but no liver disease
Reference range
People with cirrhosis and
diabetes
People with diabetes and no liver
disease P
N 29 125
Age, years 55 (49–63) 60 (50–71) 0.13
Men, n (%) 21 (72) 86 (69) 0.82
Ethnicity, n
White European 27 94 0.20
South Asian 2 16
Afro-Caribbean 0 10
Other 0 5
Severity of disease
MELD score <6 12 (9–17)*
Creatinine†, lmol/l 77 (63–110) 98 (86–112) 0.001
Glycaemic markers
Random plasma glucose, mmol/l 8.4 (7.2–11.2) 7.3 (5.3–11.5) 0.17
HbA1c, mmol/mol <48 41 (32–56) 61 (52–70) <0.001
% <6.5 5.9 (5.1–7.3) 7.7 (6.9–8.6)
Haematology
Red blood cell count, 9 1012/l Men: 4.2–5.7
Women: 3.8–5.1
3.6 (3.0–3.9)‡ 4.7(4.3–5.0) <0.001
Haemoglobin, g/l Men: 135–180
Women: 115–
165
106 (93–122)‡ 137 (125–147) <0.001
Haematocrit, l/l Men: 0.40–0.54
Women: 0.37–
0.47
0.32 (0.27–0.35)‡ 0.40 (0.38–0.43) <0.001
Mean cell volume, fl 80–99 91 (85–96) 86 (83–89) 0.001
Mean cell haemoglobin, pg 27–33 31 (28–33) 30 (28–31) 0.028
Mean cell haemoglobin
concentration, g/l
315–365 339 (327–349) 341 (329–350) 0.473
Red cell distribution width, % 11–14 17 (15–18)* 13 (13–14) <0.001
Reticulocyte count, 9109/l 20–80 61 (47–71) 45(37–64) 0.005
Platelets, 9109/l 150–450 103 (78–153)‡ 251 (214–289) <0.001
White cell count
White cell count, 109/l 4.0–11.0 5.1 (4.3–6.8) 7.2 (6.2–8.8) <0.001
Neutrophils, 109/l 2.0–7.5 3.4 (2.6–4.4) 4.3 (3.5–5.7) 0.002
Lymphocytes, 9109/l 1.0–4.0 1.1 (0.7–1.3) 2.1 (1.8–2.5) <0.001
Monocytes, 9109/l 0.2–0.8 0.5 (0.4–0.6) 0.6 (0.4–0.7) 0.064
Eosinophils, 9109/l 0.0–0.4 0.2 (0.1–0.3) 0.2 (0.1–0.3) 0.444
Median (IQR) interquartile range; otherwise n or %.
*Median higher than reference range. †Creatinine reference ranges dependent on age and gender. ‡Median lower than reference range.
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diabetes and cirrhosis had fewer white blood cells, platelets
and lymphocytes with no difference in eosinophils; all these
counts were within the reference ranges in both groups.
Associations among variables
Further investigation was undertaken to determine the
factors related to the depression of HbA1c in those with
cirrhosis using a correlation grid (Fig. 2).
There were significant differences in the magnitude and
direction of correlation coefficients for glucose between the
groups: with mean cell haemoglobin: r=–0.092 (95% CI –
0.265, 0.064) vs r=0.488 (95% CI 0.133, 0.732; P=0.010) in
the diabetes without cirrhosis group vs the diabetes and
cirrhosis group, respectively; mean cell haemoglobin con-
centration: r=–0.110 (95% CI –0.281, 0.069) vs r=0.363
(95% CI –0.018, 0.653), respectively (P=0.003, Fig. 2).
The correlation coefficients for HbA1c or glucose with the
haematological variables showed statistically significant dif-
ferences in the group with diabetes and cirrhosis. The
correlation coefficients were positive for glucose, and nega-
tive or near zero for HbA1c for: (1) mean cell volume: HbA1c,
r=–0.278 (95% CI –0.595, 0.114); glucose, r=0.387 (95% CI
0.225, 0.528; P=0.020); (2) mean cell haemoglobin: HbA1c,
r=–0.260 (95% CI –0.583, 0.132); glucose, r = 0.488 (95%
CI 0.341, 0.612; P = 0.010); (3) mean cell haemoglobin
concentration: HbA1c, r=–0.095 (95% CI –0.458, 0.296);
glucose, r=0.363 (95% CI –0.018, 0.653); (P =0.049, Fig. 2).
When stepwise regression models were applied in those
with diabetes and liver disease, red blood cell count and
eosinophils had an R2 value of 45.7% for HbA1c, and mean
cell haemoglobin and eosinophils an R2 value of 39.9% for
glucose. The most important factor determining HbA1c in
people with diabetes but no liver disease was glucose.
Severity of liver disease
The median (interquartile range) Model for End Stage Liver
Disease (MELD) score for the study cohort was calculated as
12 (9–17), (normal <6) in those with cirrhosis. The MELD
score in people with co-existing liver cirrhosis and dia-
betes was negatively correlated with HbA1c (r=0.56) and
red blood cell count (r=0.60). The correlation with glucose
was r=0.12, but MELD was positively correlated with
mean cell haemoglobin, (r=0.32) and red cell distribution
width (r=0.41).
a-1-antitrypsin disorder
The person with cirrhosis and diabetes related to a-1-
antitrypsin disorder had high HbA1c relative to glucose, with
HbA1c elevated by 28 mmol/mol (2.6%), (Fig 1). Their
FIGURE 1 HbA1c and random plasma glucose in people with diabetes with cirrhosis awaiting liver transplant and without liver disease. The person
with a-1-antitrypsin-related liver disease (blue circle) was excluded from further analyses. White diamonds: no liver disease; purple diamonds:
alcoholic liver disease; red diamonds: non-alcoholic fatty liver disease; green triangles: hepatitis C; orange circle: polycystic liver and kidneys; blue
diamonds: hereditary haemochromatosis; blue circle: a-1-antitrypsin-related liver disease; purple circle: cryptogenic/non-cirrhotic portal
hypertension. Regression line black: no liver disease; regression line red: cirrhosis. 2SD lines: no liver disease.
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haematological profile was different from that of the other
people with cirrhosis and those without cirrhosis. The plot of
haematological data for the person with a-1-antitrypsin
disorder and for others awaiting transplant (as a multiple of
the median for the group without liver disease) shows the
differences in their anaemic profiles (Fig. 3).
Discussion
Cirrhosis of the liver in people with diabetes awaiting a liver
transplant renders HbA1c unsuitable for assessing blood
glucose. In all but one person, it was associated with fewer,
larger, more irregular red blood cells. A substantial depres-
sion in HbA1c [20 mmol/mol (2%)] was observed relative to
those with diabetes but no cirrhosis across a wide range of
glucose values. This probably reflects a shorter red blood cell
half-life and less exposure of haemoglobin to glucose. In
contrast, the person with cirrhosis related to a-1-antitrypsin
disorder had a higher HbA1c level relative to glucose, with no
factors indicating anaemia, suggesting the red blood cell half-
life might be longer with more exposure to glucose.
This effect on HbA1c in people with cirrhotic liver disease
will cause misdiagnosis of diabetes and inappropriate clinical
care. In our routine clinical practice, many more depressed
FIGURE 2 Relationships of characteristics of people with cirrhosis and diabetes awaiting liver transplant, and those with diabetes. Triangles: upper for
thosewith liver disease, positive correlation coefficients, red and negative yellow; lower for thosewithout liver disease, dark blue and cyan, accordingly.
Circle size, largest for correlation +1 or –1; smallest if no correlation, i.e. 0. Shading: darker, HbA1c; lighter, glucose. Box outlines: dark blue for
statistically significant differences between HbA1c and glucose correlations (P<0.05). Black for significant differences in correlations for glucose with
variables.MELD,Model for End Stage LiverDisease; RBC, red blood cell count;Hb, haemoglobin;HCT, haematocrit;MCV,mean cell volume;MCH,
mean cell haemoglobin; MCHC, mean cell haemoglobin concentration; RDW, red cell distribution width; WBC, white blood cell count.
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than elevated HbA1c results have been noticed. We previ-
ously reported overtreatment resulting in hospital admission
in one individual with known thalassaemia as a result of
elevated HbA1c relative to glucose levels [12]. HbA1c assays
do not identify thalassaemia, although some HbA1c analysers
identify variant haemoglobins (e.g. S, F, C, D, E or rarer
types) on chromatograms.
A recent US study in 200 people (62 with diabetes) referred
for liver transplantation with decompensated cirrhosis
showed similar depression in HbA1c relative to glucose
[13]. HbA1c calculated from previous glucose results and
compared to measured HbA1c [19], was found to be
discordant by >0.5% in 49% of participants and >1.5% in
12% overall. Multivariate model analysis found haemoglo-
bin to be the only independent predictor of the larger HbA1c
discrepancies. More evidence is required regarding the extent
of the effects of liver disease on the accuracy of HbA1c for
clinical guidelines to improve on the diagnosis of diabetes
and its management.
The groups differed distinctly when their biochemistry and
haematology were compared, (Table 1 and Figs 2 and 3).
The relationships of glucose and HbA1c to red blood cell
haematology in people with diabetes and cirrhosis were
markedly different from those in people with diabetes but no
cirrhosis (Fig. 2). Low haemoglobin and macrocytosis evi-
dent in those with cirrhosis and diabetes were associated
with depression in HbA1c. The exception being the person
with a-1-antitrypsin disorder whose erythrocytes did not
display these features and whose HbA1c was elevated relative
to glucose level. Anaemia can result in either shorter or
longer erythrocyte lifespans and even differences in normal
red blood cell morphology have been shown to affect the
accuracy of HbA1c [20].
Any suspected inaccuracy in HbA1c can be confirmed using
fructosamine, unless proteinuria is present [21], and point-
of-care blood glucose testing or non-invasive continuous
blood glucose devices. The data presented on >100 people
attending the diabetes centre (along with corresponding
fructosamine results) are used in our hospital to identify any
outliers in glycaemic markers. As such, an elevated HbA1c
relative to glucose level shows when additional testing, such
as fructosamine/continuous blood glucose monitoring,
should be organized by clinicians to confirm whether HbA1c
is suitable for assessing glycaemic status. Monitoring gly-
caemia during the post-liver-transplant period is also an
issue, as it is well known that post-transplant anaemia
renders HbA1c unsuitable for clinical interpretation for ~6
months [5,22]. It is not known if this problem is resolved
after liver transplantation.
Limitations of this study include the small number of
people (29) studied with cirrhosis and diabetes compared to
the available sample with diabetes but no cirrhosis (125).
This sample size may hinder its ability to demonstrate
statistical differences between the slopes of the regression
lines. HbA1c was depressed by 25 mmol/mol (2.3%),
(P<0.001), when the study was limited to age-matched white
Eosinophils
‡Monocytes
‡Lymphocytes
‡Neutrophils
†White cell count
†Platelets
Reticulocyte count
RDW
MCHC
MCH
MCV
HCT
Hb
RBC
*†HbA1c (%)
Glucose
Creatinine
Age
0.00 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 2.50
Ratio (relative to median for those without liver disease)
FIGURE 3 Comparison of haematology in people with diabetes and cirrhosis vs those with diabetes without liver disease. Circles: red for people with
diabetes and cirrhosis, except for one person with a-1-antitrypsin disorder, which is blue. *P<0.01 for blue vs red; †P<0.01and ‡P<0.05 for blue vs
people with diabetes without liver disease. RBC, red blood cell count; Hb, haemoglobin; HCT, haematocrit; MCV, mean cell volume; MCH, mean
cell haemoglobin; MCHC, mean cell haemoglobin concentration; RDW, red cell distribution width.
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European people with liver disease (mean age 55.6 years)
compared to those without liver disease (mean age 55.3
years). As most of the participants were white European, it
cannot throw any light on the current discussion about the
relationship of HbA1c to glucose by ethnicity [23]. Although
random plasma glucose was measured rather than fasting,
this reflects routine hospital practice as is evident in other
studies [10]. Its measurement on glucose meters or blood gas
machines quality-assured by the laboratory, or measured in
the laboratory, is a quality indicator at the hospital. The
number of people studied pre-transplant was small but it
should be noted that the clinical audit was generated by
observations of inaccurate HbA1c in people with liver disease
by experts in glycaemic markers over several years of routine
clinical practice. Meta-analyses of small studies are common,
with confirmatory studies required for clinical guidelines.
Future research by our group will include more people with
conditions that affect HbA1c as outlined by WHO on more
than one clinic visit [6].
In conclusion, cirrhosis of the liver affects the accuracy of
HbA1c results, leading to unreliable estimates of blood
glucose over the previous 2 to 3 months. Anaemia in people
with cirrhosis awaiting liver transplant is associated with
altered red blood cell morphology. Significantly depressed
HbA1c was observed in all but one person with cirrhosis,
along with lower haemoglobin level and fewer, larger, less
uniform red blood cells. Visual representation of HbA1c and
random plasma glucose, along with haematology, is useful
for assessing whether HbA1c is accurate in individuals with
coexisting illnesses or on drug regimens that affect red blood
cells. Treatment targets for HbA1c arising from clinical trials
in diabetes [24,25] and cut-off values for diagnosis [7,23,26]
rely on the provision of HbA1c values that reflect circulating
glucose.
Funding sources
The G. A. Roberts Research Fund, Queen Elizabeth
Hospital Birmingham Charity, Tosoh Europe and Novo
Nordisk UK Research Foundation provided funding for the
Diabetes Translational Research Group based at Queen
Elizabeth Hospital Birmingham. The Arthur Thompson
Trust at the University of Birmingham Medical School and
the Queen Elizabeth Hospital Birmingham Charity provided
financial support for conference costs for D.B. and S.V.
when these data were presented at the American Diabetes
Association 74th Scientific Sessions, 2014 and Diabetes UK,
2015. Research by J.A.W. reported in this publication was
supported by the National Human Genome Research
Institute of the National Institutes of Health under Award
Number UM1HG006370. The content is solely the respon-
sibility of the authors and does not necessarily represent the
official views of the National Institutes of Health. G.V.G.
acknowledges support from H2020-EINFRA (731075) and
the National Science Foundation (IOS:1340112) as well as
support from the NIHR Birmingham ECMC, NIHR Birm-
ingham SRMRC and the NIHR Birmingham Biomedical
Research Centre and the MRC HDR UK. The views
expressed in this publication are those of the authors and
not necessarily those of the NHS, the National Institute for
Health Research, the Medical Research Council or the
Department of Health. The funding organizations had no
role in the design of this study, data collection, analysis or
interpretation, or preparation of the manuscript, and did
not approve or disapprove of, or delay publication of the
work.
Competing interests
None declared.
Acknowledgements
The laboratory measurements were produced by the biomed-
ical scientists in Clinical Laboratory Sciences at Queen
Elizabeth Hospital Birmingham. We would like to thank Dr
Radhika Susarla (Research Scientist, Diabetes Translational
Research Group) for her assistance with the manuscript. We
would also like to thank Dr Paul Cockwell (Consultant
Nephrologist, Renal Medicine, Queen Elizabeth Hospital
Birmingham) and Professor Wasim Hanif (Professor of
Diabetes and Endocrinology, Diabetes Centre, Queen Eliz-
abeth Hospital Birmingham) for their support and encour-
agement.
Data access statement
The datasets generated during and/or analysed during the
study are not publicly available. The dataset contains clinical
data which cannot be shared publicly as a result of UK data
protection legislation.
References
1 Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver
disease in type 2 diabetes and management of patients with diabetes
and liver disease. Diabetes Care 2007; 30: 734–743.
2 Ahmadieh H, Azar ST. Liver disease and diabetes: association,
pathophysiology, and management. Diabetes Res Clin Pract 2014;
104: 53–62.
3 Lecube A, Hernandez C, Genesca J, Simo R. Proinflammatory
cytokines, insulin resistance, and insulin secretion in chronic
hepatitis C patients: A case-control study. Diabetes Care 2006;
29: 1096–1101.
4 Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA,
Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors,
pathophysiology, clinical implications and management. World J
Gastroenterol 2009; 15: 280–288.
5 Shivaswamy V, Boerner B, Larsen J. Post-Transplant Diabetes
Mellitus: Causes, Treatment, and Impact on Outcomes. Endocr Rev
2016; 37: 37–61.
6 Webber J, Chua S, Cockwell P, Haydon G, Jobanputra P, Lester W
et al. Effects of concurrent illnesses and treatments on surrogate
8
ª 2019 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK
DIABETICMedicine HbA1c before liver transplant  D. Bhattacharjee et al.
glycaemic markers. Diabet Med 2017; 34 (Suppl. 1): P138
(Abstract).
7 Report of a World Health Organization Consultation. Use of
glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus.
Diabetes Res Clin Pract 2011;93:299–309.
8 Dowd RP, Manning PW, Ahmed N, Mason CL, Round RA,
Nightingale PG et al. Post introduction of HbA1c as a diagnostic
test: consequences for requesting and reporting. Diabet Med 2015;
32 (Suppl. 1): P440.
9 American Diabetes Association. Position statement. Diagnosis and
classification of diabetes mellitus. Diabetes Care 2014; 37 (Suppl.
1): S81–S90.
10 ManleySE,O’BrienKT,QuinlanD,RoundRA,NightingalePG,AliF
et al. Can HbA1c detect undiagnosed diabetes in acute medical
hospital admissions?Diabetes Res Clin Pract 2016; 115: 106–114.
11 Dowd RP, Round RA, Mason CL, Nightingale PG, Ghosh SG,
Hanif W et al. Review of HbA1c results >120 mmol/mol as patients
may require urgent assessment if request for diagnosis of Type 2
diabetes. Diabet Med 2014; 31 (Suppl 1): P466.
12 Kadri F, Stuart K, Cramb R, Manley S, Mtemererwa B, Ghosh S.
HbA1c interpretation and its caveats: a case of targeting apparently
good glycaemic control causing severe hypoglycaemia. Interna-
tional Diabetes Federation (IDF) meeting, Vancouver, Canada, 30
November to 4 December, 2015. Abstract: 0550-P.
13 Nadelson J, Satapathy SK, Nair S. Glycated hemoglobin levels in
patients with decompensated cirrhosis. Int J Endocrinol 2016;
2016: Article ID 8390210. https://doi.org/10.1155/2016/8390210.
14 Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg
PC. A model to predict poor survival in patients undergoing
transjugular intrahepatic portosystemic shunts. Hepatology 2000;
31: 864–871.
15 Manley SE, Hikin LJ, Round RA, Manning PW, Luzio SD,
Dunseath GJ et al. Comparison of IFCC-calibrated HbA1c from
laboratory and point of care testing systems. Diabetes Res Clin
Pract 2014; 105: 364–372.
16 R Core Team. R: A language and environment for statistical
computing. Vienna, Austria: R Foundation for Statistical
Computing; 2017. Available at https://www.R-project.org/. Last
accessed 19 December 2017.
17 Wei T, Simko V. R package “corrplot”: Visualization of a
Correlation Matrix (Version 0.84) 2017. Available at https://
github.com/taiyun/corrplot. Last accessed 19 December 2017
18 Revelle, W. psych: Procedures for Personality and Psychological
Research (Version 1.7.8) 2017. Northwestern University, Evan-
ston, Illinois, USA. Available at https://CRAN.R-project.org/packa
ge=psych. Last accessed 19 December 2017.
19 Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ.
Translating the A1C assay into estimated average glucose values.
Diabetes Care 2008; 31: 1473–1478.
20 Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, Ciraolo
PJ et al. Red cell life span heterogeneity in hematologically normal
people is sufficient to alter HbA1c. Blood 2008; 112: 4284–4291.
21 Manley SE, Round RA, Nightingale PG, Stratton IM, Cramb R,
Gough SC. How is fructosamine affected by urinary albumin
excretion? Diabetes 2011; 60(Suppl 1): A584.
22 Eide IA, Halden TA, Hartmann A, Asberg A, Dahle DO, Reisæter
AV et al. Limitations of hemoglobin A1c for the diagnosis of
posttransplant diabetes mellitus. Transplantation 2015; 99: 629–
635.
23 American Diabetes Association. 2. Classification and diagnosis of
diabetes: standards of medical care in diabetes-2018.Diabetes Care
2018; 41 (Suppl. 1): S13–S27.
24 DCCT Study Group. The relationship of glycemic exposure
(HbA1c) to the risk of development and progression of retinopathy
in the diabetes control and complications trial. Diabetes 1995; 44:
968–983.
25 UK Prospective Diabetes Study Group. UK Prospective Diabetes
Study (UKPDS) 35. Association of glycaemia with macrovascular
and microvascular complications of type 2 diabetes : prospective
observational study. BMJ 2000; 321: 405–412.
26 Manley S, Nightingale P, Stratton I, Sikaris K, Smith J, Cramb R
et al. Diagnosis of diabetes: HbA1c versus WHO criteria. Diabetes
Prim Care 2010; 12: 87–96.
ª 2019 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK 9
Research article DIABETICMedicine
